175 related articles for article (PubMed ID: 24421342)
21. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
22. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
23. A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.
D'Avino C; Palmieri D; Braddom A; Zanesi N; James C; Cole S; Salvatore F; Croce CM; De Lorenzo C
Oncotarget; 2016 Dec; 7(52):87016-87030. PubMed ID: 27894092
[TBL] [Abstract][Full Text] [Related]
24. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
Huang X; Gao L; Wang S; McManaman JL; Thor AD; Yang X; Esteva FJ; Liu B
Cancer Res; 2010 Feb; 70(3):1204-14. PubMed ID: 20103628
[TBL] [Abstract][Full Text] [Related]
25. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
26. A novel ErbB2 epitope targeted by human antitumor immunoagents.
Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
[TBL] [Abstract][Full Text] [Related]
27. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.
Lu Q; Wang L; Zhang Y; Yu X; Wang C; Wang H; Yang Y; Chong X; Xia T; Meng Y; Wang Y; Lu C; Zhou L; Li B
Oncotarget; 2016 Oct; 7(41):67129-67141. PubMed ID: 27564098
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
29. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.
De Lorenzo C; Arciello A; Cozzolino R; Palmer DB; Laccetti P; Piccoli R; D'Alessio G
Cancer Res; 2004 Jul; 64(14):4870-4. PubMed ID: 15256457
[TBL] [Abstract][Full Text] [Related]
30. Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab.
Barth AS; Zhang Y; Li T; Smith RR; Chimenti I; Terrovitis I; Davis DR; Kizana E; Ho AS; O'Rourke B; Wolff AC; Gerstenblith G; Marbán E
Stem Cells Transl Med; 2012 Apr; 1(4):289-97. PubMed ID: 23197808
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
32. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
[TBL] [Abstract][Full Text] [Related]
33. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
[TBL] [Abstract][Full Text] [Related]
34. Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.
Wang Q; Ding H; Liu B; Li SH; Li P; Ge H; Zhang K
Int J Oncol; 2014 Apr; 44(4):1277-83. PubMed ID: 24452693
[TBL] [Abstract][Full Text] [Related]
35. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
[TBL] [Abstract][Full Text] [Related]
36. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
38. T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells.
Riccio G; Ricardo AR; Passariello M; Saraiva K; Rubino V; Cunnah P; Mertens N; De Lorenzo C
J Immunother; 2019 Jan; 42(1):1-10. PubMed ID: 30520849
[TBL] [Abstract][Full Text] [Related]
39. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
[TBL] [Abstract][Full Text] [Related]
40. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]